Pfizer Statistics
Total Valuation
Pfizer has a market cap or net worth of $169.83 billion. The enterprise value is $227.44 billion.
| Market Cap | 169.83B |
| Enterprise Value | 227.44B |
Important Dates
The next confirmed earnings date is Tuesday, July 30, 2024, before market open.
| Earnings Date | Jul 30, 2024 |
| Ex-Dividend Date | Jul 26, 2024 |
Share Statistics
Pfizer has 5.67 billion shares outstanding. The number of shares has decreased by -0.52% in one year.
| Shares Outstanding | 5.67B |
| Shares Change (YoY) | -0.52% |
| Shares Change (QoQ) | +0.05% |
| Owned by Insiders (%) | 0.05% |
| Owned by Institutions (%) | 68.30% |
| Float | 5.66B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 11.90 |
| PS Ratio | 3.08 |
| Forward PS | 2.68 |
| PB Ratio | 1.84 |
| P/FCF Ratio | 33.26 |
| PEG Ratio | 0.26 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 48.46, with an EV/FCF ratio of 44.54.
| EV / Earnings | n/a |
| EV / Sales | 4.13 |
| EV / EBITDA | 48.46 |
| EV / EBIT | n/a |
| EV / FCF | 44.54 |
Financial Position
The company has a current ratio of 1.05, with a Debt / Equity ratio of 0.75.
| Current Ratio | 1.05 |
| Quick Ratio | 0.57 |
| Debt / Equity | 0.75 |
| Debt / EBITDA | 14.82 |
| Debt / FCF | 13.62 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -0.30% and return on invested capital (ROIC) is -1.11%.
| Return on Equity (ROE) | -0.30% |
| Return on Assets (ROA) | -0.10% |
| Return on Capital (ROIC) | -1.11% |
| Revenue Per Employee | $626,068 |
| Profits Per Employee | -$3,511 |
| Employee Count | 88,000 |
| Asset Turnover | 0.25 |
| Inventory Turnover | 2.30 |
Taxes
| Income Tax | -1.54B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -17.76% in the last 52 weeks. The beta is 0.63, so Pfizer's price volatility has been lower than the market average.
| Beta (5Y) | 0.63 |
| 52-Week Price Change | -17.76% |
| 50-Day Moving Average | 28.41 |
| 200-Day Moving Average | 28.50 |
| Relative Strength Index (RSI) | 66.23 |
| Average Volume (20 Days) | 31,764,134 |
Short Selling Information
The latest short interest is 59.89 million, so 1.06% of the outstanding shares have been sold short.
| Short Interest | 59.89M |
| Short Previous Month | 75.97M |
| Short % of Shares Out | 1.06% |
| Short % of Float | 1.06% |
| Short Ratio (days to cover) | 1.74 |
Income Statement
In the last 12 months, Pfizer had revenue of $55.09 billion and -$309.00 million in losses. Loss per share was -$0.05.
| Revenue | 55.09B |
| Gross Profit | 31.65B |
| Operating Income | -1.79B |
| Pretax Income | -1.85B |
| Net Income | -309.00M |
| EBITDA | 4.69B |
| EBIT | -1.85B |
| Loss Per Share | -$0.05 |
Balance Sheet
The company has $11.93 billion in cash and $69.54 billion in debt, giving a net cash position of -$57.61 billion or -$10.17 per share.
| Cash & Cash Equivalents | 11.93B |
| Total Debt | 69.54B |
| Net Cash | -57.61B |
| Net Cash Per Share | -$10.17 |
| Equity (Book Value) | 92.28B |
| Book Value Per Share | 16.29 |
| Working Capital | 1.92B |
Cash Flow
In the last 12 months, operating cash flow was $8.58 billion and capital expenditures -$3.47 billion, giving a free cash flow of $5.11 billion.
| Operating Cash Flow | 8.58B |
| Capital Expenditures | -3.47B |
| Free Cash Flow | 5.11B |
| FCF Per Share | $0.90 |
Margins
Gross margin is 57.44%, with operating and profit margins of -3.25% and -0.56%.
| Gross Margin | 57.44% |
| Operating Margin | -3.25% |
| Pretax Margin | -3.35% |
| Profit Margin | -0.56% |
| EBITDA Margin | 8.52% |
| EBIT Margin | -3.35% |
| FCF Margin | 9.27% |
Dividends & Yields
This stock pays an annual dividend of $1.68, which amounts to a dividend yield of 5.61%.
| Dividend Per Share | $1.68 |
| Dividend Yield | 5.61% |
| Dividend Growth (YoY) | 2.45% |
| Years of Dividend Growth | 13 |
| Payout Ratio | n/a |
| Buyback Yield | 0.52% |
| Shareholder Yield | 6.13% |
| Earnings Yield | -0.18% |
| FCF Yield | 3.01% |
Analyst Forecast
The average price target for Pfizer is $35.69, which is 19.09% higher than the current price. The consensus rating is "Buy".
| Price Target | $35.69 |
| Price Target Difference | 19.09% |
| Analyst Consensus | Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (5Y) | 1.48% |
| EPS Growth Forecast (5Y) | 50.72% |
Stock Splits
The last stock split was on November 17, 2020. It was a forward split with a ratio of 1054:1000.
| Last Split Date | Nov 17, 2020 |
| Split Type | Forward |
| Split Ratio | 1054:1000 |
Scores
Pfizer has an Altman Z-Score of 1.79 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.79 |
| Piotroski F-Score | 2 |